Table 3.
Objective response by prior treatment and subtype
| All evaluable (N=42) | Prior lines of chemotherapy in metastatic setting | Prior taxane exposure | Subtype | |||||
|---|---|---|---|---|---|---|---|---|
| Response – N (%) | 0 (N=9) |
1 (N=20) |
≥2 (N=13) |
Yes (N=36) |
No (N=6) |
ER/PgR+b (N=30) |
TNBC (N=12) |
|
| ORR | 25 (59%) | 6 (67%) | 13 (65%) | 6 (46%) | 22 (61%) | 3 (50%) | 18 (60%) | 7 (58%) |
| CR | 3 (7%) | 0 (0%) | 2 (10%) | 1 (8%) | 3 (8%) | 0 (0%) | 1 (3%) | 2 (17%) |
| PR | 22 (52%) | 6 (67%) | 11 (55%) | 5 (38%) | 19 (53%) | 3 (50%) | 17 (57%) | 5 (42%) |
| SD ≥16 weeks | 9 (21%) | 1 (11%) | 4 (20%) | 4 (31%) | 7 (19%) | 2 (33%) | 9 (30%) | 0 (0%) |
| CBRa | 34 (80%) | 7 (78%) | 17 (85%) | 10 (77%) | 29 (81%) | 5 (83%) | 27 (90%) | 7 (58%) |
a
CR + PR + SD ≥16 weeks
b
ER and/or PgR positivity defined as ≥10% by immunohistochemistry.
Abbreviations: CBR; clinical benefit rate; CR, complete response; ER, estrogen receptor; ORR, overall response rate; PgR, progesterone receptor; PR, partial response; SD, stable disease; TNBC, triple-negative breast cancer.